STOCK TITAN

Capricor Therapeutics Inc - CAPR STOCK NEWS

Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.

Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.

Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.

Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.

Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced that the FDA has scheduled a Pre-BLA meeting in Q3 2024 for the company's lead product, deramiocel (CAP-1002), aimed at treating Duchenne Muscular Dystrophy (DMD). The meeting will finalize BLA filing plans and outline a rolling submission timeline. Capricor's CEO, Linda Marbán, emphasized the urgency due to the unmet needs of DMD patients and the potential of deramiocel as an anchor therapy. Additionally, Capricor will present the latest 36-month data from the HOPE-2 Open Label Extension (OLE) study at the Parent Project Muscular Dystrophy 30th Annual Conference from June 27-29, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could streamline regulatory review and reduce risks. The company also received positive clinical results from their HOPE-2 and HOPE-2 OLE studies, with additional data pending from the HOPE-3 trial. The WHO selected 'Deramiocel' as the International Nonproprietary Name for CAP-1002. Capricor could also receive a Priority Review Voucher following FDA approval due to its rare pediatric disease designation. This regulatory progress signifies pivotal steps toward the potential commercialization of CAP-1002.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) has announced positive 3-year results from their HOPE-2 open-label extension (OLE) study involving CAP-1002 for treating Duchenne muscular dystrophy (DMD). The study showed continued benefits in skeletal muscle function and cardiac function, with patients experiencing a statistically significant reduction in the decline of upper limb function (PUL 2.0) and stabilization in left ventricular ejection fraction (LVEF). These results were recently shared with the FDA at a Type-B meeting in May 2024, and detailed results will be presented at the Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference in late June 2024. The company plans to release topline results from their Phase 3 HOPE-3 pivotal trial in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced its Q1 2024 financial results and provided a corporate update. Key highlights include the completion of enrollment for the HOPE-3 Phase 3 trial (Cohort A) of CAP-1002 for Duchenne Muscular Dystrophy (DMD) and the receipt of a $10 million milestone payment from Nippon Shinyaku. Capricor held a successful Type-B CMC FDA meeting and plans to report 3-year HOPE-2 OLE data in Q2 2024. Financially, the company reported $4.9 million in Q1 2024 revenues, up from $3 million in Q1 2023, with a net loss of $9.8 million. Capricor's cash position stands at $39.9 million, sufficient to cover expenses into Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
-
Rhea-AI Summary

Capricor Therapeutics is set to present updates on its exosome platform technology at the ASGCT 27th Annual Meeting, showcasing a potential exosome-based approach for treating arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease. The preclinical findings demonstrate the therapeutic potential of Capricor's StealthX™ exosome platform technology in delivering enzyme-replacement therapies. The company aims to leverage partnership opportunities to advance its exosome platform for therapeutic and vaccine development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
-
Rhea-AI Summary

Capricor Therapeutics (CAPR) is set to present at various upcoming scientific and medical conferences, showcasing their transformative cell and exosome-based therapeutics for rare diseases. The company will be discussing potential applications for the treatment of rare diseases like Arginase-1 Deficiency and Duchenne Muscular Dystrophy. The presentations will cover advancements in targeted cargo delivery and disease modification in later-stage patients. These conferences provide a platform for Capricor to share their innovative research and progress in the biotechnology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
conferences
Rhea-AI Summary

Capricor Therapeutics, a biotechnology company focusing on cell and exosome-based therapeutics for rare diseases, will announce its first quarter 2024 financial results on May 13, 2024. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to provide a corporate update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences earnings
-
Rhea-AI Summary
Capricor Therapeutics announces positive outcomes from a Type-B meeting with the FDA regarding the CAP-1002 program for Duchenne Muscular Dystrophy. The FDA supports requests for a Pre-BLA meeting and Rolling BLA submission, aligning with the company on non-clinical comparability. Capricor plans to share 3-year safety and efficacy data with the FDA in the second quarter of 2024. The company is on track to potentially accelerate the BLA filing process for CAP-1002 treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
-
Rhea-AI Summary
Capricor Therapeutics (CAPR) to present at H.C. Wainwright and Cantor Fitzgerald conferences to discuss progress on CAP-1002 for Duchenne muscular dystrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
Rhea-AI Summary
Capricor Therapeutics (CAPR) announces positive 24-month results from HOPE-2 open-label extension study of CAP-1002 in Duchenne Muscular Dystrophy. The study shows significant improvements in skeletal and cardiac muscle function, with a 64% reduction in disease progression. CAP-1002 demonstrates a favorable safety profile and potential long-term benefits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
none
Capricor Therapeutics Inc

Nasdaq:CAPR

CAPR Rankings

CAPR Stock Data

513.86M
38.00M
16.84%
38.26%
17.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEVERLY HILLS